EP2991650A4 - Méthodes de traitement du cancer - Google Patents

Méthodes de traitement du cancer Download PDF

Info

Publication number: EP2991650A4
Authority: EP; European Patent Office
Prior art keywords: cancer; treatment; methods
Prior art date: 2013-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14791444.4A

Other languages

German (de)

English (en)

Other versions

EP2991650A1 (fr

Inventor

Robert Goodenow

Peter Ordentlich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Syndax Pharmaceuticals Inc

Original Assignee

Syndax Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-03

Filing date

2014-05-02

Publication date

2017-01-25

2014-05-02 Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc

2016-03-09 Publication of EP2991650A1 publication Critical patent/EP2991650A1/fr

2017-01-25 Publication of EP2991650A4 publication Critical patent/EP2991650A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Inorganic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP14791444.4A 2013-05-03 2014-05-02 Méthodes de traitement du cancer Withdrawn EP2991650A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361819505P	2013-05-03	2013-05-03
PCT/US2014/036651 WO2014179738A1 (fr)	2013-05-03	2014-05-02	Méthodes de traitement du cancer

Publications (2)

Publication Number	Publication Date
EP2991650A1 EP2991650A1 (fr)	2016-03-09
EP2991650A4 true EP2991650A4 (fr)	2017-01-25

Family

ID=51843995

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14791444.4A Withdrawn EP2991650A4 (fr)	2013-05-03	2014-05-02	Méthodes de traitement du cancer

Country Status (6)

Country	Link
EP (1)	EP2991650A4 (fr)
JP (2)	JP2016522188A (fr)
KR (1)	KR102337598B1 (fr)
CN (1)	CN105492007A (fr)
HK (1)	HK1223547A1 (fr)
WO (1)	WO2014179738A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3313433A4 (fr) *	2015-06-29	2019-01-02	Syndax Pharmaceuticals Inc.	Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pdl-1 pour le traitement du cancer
US20190282541A1 (en) *	2016-07-20	2019-09-19	Eisai R&D Management Co., Ltd.	Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
WO2018213665A1 (fr)	2017-05-19	2018-11-22	Syndax Pharmaceuticals, Inc.	Polythérapies
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
RU2680603C1 (ru) *	2018-11-08	2019-02-25	Ильясов Шамиль Сионович	Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007011148A (es) *	2005-03-11	2008-02-22	Univ Colorado	Inhibidores de histona desacetilasa que sensibilizan celulas cancerosas respecto a los inhibidores de factor de crecimiento.
RU2009104001A (ru) *	2006-07-11	2010-08-20	Мьючуал Фармасьютикал Компани, Инк. (Us)	Композиции с контролируемым высвобождением
US20100305167A1 (en) *	2007-11-19	2010-12-02	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC
US20110002989A1 (en) *	2008-03-07	2011-01-06	Pfizer Inc.	Methods, dosage forms and kits for administering ziprasidone without food
US20110182888A1 (en) *	2008-04-08	2011-07-28	Peter Ordentlich	Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
MX358254B (es) *	2011-09-02	2018-08-10	Syndax Pharmaceuticals Inc	Métodos para el tratamiento de cáncer de mama.

2014
- 2014-05-02 KR KR1020157033947A patent/KR102337598B1/ko active Active
- 2014-05-02 HK HK16111783.0A patent/HK1223547A1/zh unknown
- 2014-05-02 WO PCT/US2014/036651 patent/WO2014179738A1/fr not_active Ceased
- 2014-05-02 JP JP2016512076A patent/JP2016522188A/ja active Pending
- 2014-05-02 EP EP14791444.4A patent/EP2991650A4/fr not_active Withdrawn
- 2014-05-02 CN CN201480038420.7A patent/CN105492007A/zh active Pending
2019
- 2019-02-15 JP JP2019026073A patent/JP6860949B2/ja active Active

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01594398 on 2012_07_31: ClinicalTrials.gov Archive", 31 July 2012 (2012-07-31), XP055323902, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01594398/2012_07_31> [retrieved on 20161129] *
L. GORE ET AL: "A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas", CLINICAL CANCER RESEARCH, vol. 14, no. 14, 15 July 2008 (2008-07-15), US, pages 4517 - 4525, XP055323917, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1461 *
NILOFER AZAD ET AL: "The future of epigenetic therapy in solid tumours-lessons from the past", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 10, no. 5, 2 April 2013 (2013-04-02), NY, US, pages 256 - 266, XP055324023, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2013.42 *
S. KUMMAR ET AL: "Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies", CLINICAL CANCER RESEARCH, vol. 13, no. 18, 15 September 2007 (2007-09-15), US, pages 5411 - 5417, XP055323928, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-0791 *
See also references of WO2014179738A1 *

Also Published As

Publication number	Publication date
JP2016522188A (ja)	2016-07-28
CN105492007A (zh)	2016-04-13
KR20160003182A (ko)	2016-01-08
JP2019112416A (ja)	2019-07-11
HK1223547A1 (zh)	2017-08-04
KR102337598B1 (ko)	2021-12-10
EP2991650A1 (fr)	2016-03-09
WO2014179738A1 (fr)	2014-11-06
JP6860949B2 (ja)	2021-04-21

Publication	Publication Date	Title
EP3027192A4 (fr)	2017-03-22	Méthodes permettant de traiter des tumeurs solides
EP2964028A4 (fr)	2017-06-07	Composés pour le traitement du cancer
EP3076977A4 (fr)	2017-08-16	Polythérapie pour le traitement du cancer
EP3033079A4 (fr)	2017-04-05	Méthodes de traitement d'un cancer amplifié par her2
EP3030323A4 (fr)	2017-01-11	Inhibiteurs de kdm1a pour le traitement d'une maladie
PL3033086T3 (pl)	2022-01-31	Terapia skojarzona do leczenia nowotworów złośliwych
EP2968254A4 (fr)	2017-03-15	Procédés de traitement du cancer du poumon
EP3057594A4 (fr)	2017-06-07	Méthode de traitement du cancer
EP3004396A4 (fr)	2017-03-01	Méthodes et compositions pour le traitement du cancer
PT3089749T (pt)	2019-09-06	Preparações combinadas para o tratamento de cancro
EP2994148B8 (fr)	2017-08-30	Thérapie du cancer
EP3007756A4 (fr)	2017-02-22	Traitement de tumeur assiste par catheter
EP3008212A4 (fr)	2017-05-24	Méthodes de traitement du cancer
EP3062790A4 (fr)	2017-05-24	Combinaisons pharmaceutiques pour le traitement du cancer
EP3003489A4 (fr)	2017-02-08	Agents cytotoxiques destinés au traitement du cancer
IL242546A0 (en)	2016-02-01	New compounds for cancer treatment
EP3074040A4 (fr)	2017-06-28	Méthode de traitement du cancer
EP3057593A4 (fr)	2017-03-08	Traitement du cancer du pancréas
EP3044593A4 (fr)	2017-05-17	Traitement du cancer
EP3011013A4 (fr)	2017-03-15	Procédé pour le traitement d'un cancer de l'ovaire
EP2991650A4 (fr)	2017-01-25	Méthodes de traitement du cancer
EP3252171B8 (fr)	2021-12-15	Méthodes de traitement du cancer
EP3089745A4 (fr)	2017-05-17	Composés, compositions et méthodes de traitement de cancers
EP3049078A4 (fr)	2017-05-10	Traitement du cancer
EP3016948B8 (fr)	2017-07-19	2-acylaminothiazoles pour le traitement de cancer

Legal Events

Date	Code	Title	Description
2016-02-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-03-09	17P	Request for examination filed	Effective date: 20151203
2016-03-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-03-09	AX	Request for extension of the european patent	Extension state: BA ME
2016-08-10	DAX	Request for extension of the european patent (deleted)
2017-01-25	A4	Supplementary search report drawn up and despatched	Effective date: 20161223
2017-01-25	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20161219BHEP Ipc: A61K 31/5685 20060101ALI20161219BHEP Ipc: A61K 31/4406 20060101AFI20161219BHEP
2017-08-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2019-02-20	18W	Application withdrawn	Effective date: 20190111